Antibody Information

General Information of This Antibody

Antibody ID	ANI0AZDGN
Antibody Name	Anti-CD30 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Alpha-CD30-9 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.90% (Day 16)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-9 (1.2 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR+ DEL/BVR ALCL cells with CD30 expression with high expression.
In Vivo Model	DEL/BVR CDX model
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.70% (Day 28)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-9 (0.5 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR-L540cy HL cells with CD30 expression with high expression.
In Vivo Model	L540cy CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens

Alpha-CD30-7 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.10% (Day 28)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-7 (0.3 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR-L540cy HL cells with CD30 expression with high expression.
In Vivo Model	L540cy CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 16)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-7 (1 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR+ DEL/BVR ALCL cells with CD30 expression with high expression.
In Vivo Model	DEL/BVR CDX model
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170

Alpha-CD30-8 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.10% (Day 28)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-8 (0.3 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR-L540cy HL cells with CD30 expression with high expression.
In Vivo Model	L540cy CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.20% (Day 16)	Positive CD30 expression (CD30+++/++)
Method Description	Alpha-CD30-8 (1 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of CD30+, MDR+ DEL/BVR ALCL cells with CD30 expression with high expression.
In Vivo Model	DEL/BVR CDX model
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170

References

Ref 1	Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR(+) and Heterogeneous Tumor Models. Mol Cancer Ther. 2018 Aug;17(8):1752-1760. doi: 10.1158/1535-7163.MCT-18-0073. Epub 2018 Jun 4.